Search PubMed⌕ Search

Biomedical subjects

A J Wagner

Publications and source records attributed to A J Wagner.

29 records · Page 2Linked to original sources

Myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21waf1/cip1.

Deregulated expression of the c-myc proto-oncogene can lead to apoptosis under certain physiological conditions. By introducing a conditionally active Myc allele into primary embryo fibroblasts null for p53, and into fibroblasts without endogenous p53 expression but ectopically expressing a temperature-sensitive p53 allele, we show that expression of wild-type p53 is required for susceptibility to Myc-mediated apoptosis. Although ectopic expression of wild-type p53 blocked cells in the G1 phase of the cell cycle, G1 arrest by isoleucine starvation, in a manner independent of p53, did not confer susceptibility to apoptosis. Thus, growth arrest per se is not sufficient to induce Myc-mediated apoptosis; instead, a property intrinsic to p53 is specifically required. Moreover, apoptosis did not require induction of p53 target proteins, including the cyclin-dependent kinase inhibitor p21waf1/cip1. Therefore, the role of p53 in apoptosis may be distinct from its role in cell cycle arrest.

Alleles↗

Sequence-specific transcriptional activation by Myc and repression by Max.

The c-Myc oncoprotein, which is required for cellular proliferation, resembles in its structure a growing number of transcription factors. However, the mechanism of its action in vivo is not yet clear. The discovery of the specific cognate DNA-binding site for Myc and its specific heterodimerization partner, Max, enabled the use of direct experiments to elucidate how Myc functions in vivo and how this function is modulated by Max. Here we demonstrate that exogenously expressed Myc is capable of activating transcription in vivo through its specific DNA-binding site. Moreover, transcriptional activation by Myc is dependent on the basic region, the integrity of the helix-loop-helix and leucine zipper dimerization motifs located in the carboxy-terminal portion of the protein, and the regions in the amino terminus conserved among Myc family proteins. In contrast to Myc, exogenously expressed Max elicited transcriptional repression and blocked transcriptional activation by Myc through the same DNA-binding site. Our results suggest a functional antagonism between Myc and Max which is mediated by their relative levels in the cells. A model for the activity of Myc and Max in vivo is presented.

Base Sequence↗

Myc-mediated apoptosis is blocked by ectopic expression of Bcl-2.

The product of the c-myc proto-oncogene is an important positive regulator of cell growth and proliferation. Recently, c-Myc has also been demonstrated to be a potent inducer of apoptosis when expressed in the absence of serum or growth factors. To further examine Myc-induced apoptosis, we coexpressed the proto-oncogene bcl2, which has been shown to block apoptosis in other systems, with c-myc in serum-deprived Rat 1a fibroblasts. Here we report that ectopic expression of bcl2 specifically blocks apoptosis induced by constitutive c-myc expression. Constitutive c-myc expression in serum-deprived Rat 1a cells caused a > 15-fold increase in the number of dead cells, accompanied by DNA fragmentation. However, coexpression of bcl2 with c-myc in these cells led to a 10-fold increase in the number of live cells and a significant decrease in DNA fragmentation. Thus, Bcl-2 effectively inhibits Myc-induced apoptosis in serum-deprived Rat 1a fibroblasts without blocking entry into the cell cycle. These results imply that apoptosis serves as a protective mechanism to prevent tumorigenicity elicited by deregulated Myc expression. This protective mechanism is abrogated, however, by Bcl-2 and therefore may explain the synergism between Myc and Bcl-2 observed in certain tumor cells.

Animals↗

c-Myc induces the expression and activity of ornithine decarboxylase.

The role of the product of the c-myc protooncogene in the regulation of cellular proliferation and differentiation is well established. Recent reports that c-Myc can serve as a sequence-specific transcriptional activator have begun to elucidate the mechanism by which c-Myc exerts such a profound effect on the mitotic status of a cell. To identify a potential target gene for Myc-mediated trans-activation, we examined the regulation of the ornithine decarboxylase (ODC) gene by c-Myc. ODC is the first and rate-limiting enzyme involved in the synthesis of the polyamines and has been shown to be required for entry into and progression through the cell cycle. Using a conditionally active c-Myc-estrogen receptor chimeric protein, we found estrogen-dependent activation of ODC expression and enzymatic activity. The induction of ODC mRNA expression was not dependent upon de novo protein synthesis. These data suggest that one downstream pathway for Myc-directed cell cycle control is the induction of ODC expression.

3T3 Cells↗

Scanning slit mammography.

The importance of scatter in mammography and the performance of conventional mammographic grids are reviewed. Without scatter control image contrast is significantly degraded. Conventional mammography grids improve the situation; however, their performance is limited. As a result for 5 to 8 cm thick breasts, a more ideal method of scatter control could result in a 25 to 45% improvement in contrast over that possible with conventional grids. One such approach is scanning slit mammography. The principles of this approach are presented along with the design and geometrical specifications of a prototype multiple scanning slit unit. The unit has a measured primary transmission of 91% and scatter transmission of 3%. Similarly measured performance values for a commonly used grid are 62% and 19%, respectively. Compared are images of a 6 cm breast phantom obtained with the scanning slit unit and a conventional grid. The scanning slit unit achieved noticeably greater image contrast with 30% less radiation. Also discussed are the limitations and engineering challenges of the technology.

Image Processing, Computer-Assisted↗

Expression, regulation, and chromosomal localization of the Max gene.

The Max gene encodes a protein that interacts specifically with the Myc protein to form a heterodimer with high affinity for the specific cognate DNA binding site of Myc. Here we examine the expression of Max RNA in comparison to Myc RNA during cell growth and differentiation. Two species of RNA, a major 2.0- and a minor 1.7-kilobase species, hybridized specifically to a Max cDNA probe in all human and murine cell lines that were tested. Unlike Myc, the steady-state level of Max RNA is not significantly modulated with respect to proliferation or differentiation. Max RNA is expressed in quiescent BALB/c 3T3 cells and is modestly increased 3 h after addition of serum to the quiescent cells. In contrast to Myc RNA, Max RNA does not decline immediately upon induction of differentiation of HL60 cells by dimethyl sulfoxide, and only a modest decrease of Max RNA was observed 72 h after induction of differentiation. Unlike Myc RNA, Max RNA is relatively stable with a half-life of greater than 3 h and, therefore, does not exhibit the characteristic short half-life of RNAs encoded by most immediate early genes. The human Max gene was localized to chromosome 14, band q23. With respect to the recurring abnormalities in human tumors, this region of chromosome 14 is involved in deletions in B-cell chronic lymphocytic leukemia and malignant lymphomas and in the 12;14 translocation in uterine leiomyomas.

Animals↗

Tubuloglomerular feedback dynamics and renal blood flow autoregulation in rats.

To decide whether tubuloglomerular feedback (TGF) can account for renal autoregulation, we tested predictions of a TGF simulation. Broad-band and single-frequency perturbations were applied to arterial pressure; arterial blood pressure, renal blood flow and proximal tubule pressure were measured. Data were analyzed by linear systems analysis. Broad-band forcings of arterial pressure were also applied to the model to compare experimental results with simulations. With arterial pressure as the input and tubular pressure, renal blood flow, or renal vascular resistance as outputs, the model correctly predicted gain and phase only in the low-frequency range. Experimental results revealed a second component of vascular control active at 100-150 mHz that was not predicted by the simulation. Forcings at single frequencies showed that the system behaves linearly except in the band of 33-50 mHz in which, in addition, there are autonomous oscillations in TGF. Higher amplitude forcings in this band were attenuated by autoregulatory mechanisms, but low-amplitude forcings entrained the autonomous oscillations and provoked amplified oscillations in blood flow, showing an effect of TGF on whole kidney blood flow. We conclude that two components can be detected in the dynamic regulation of renal blood flow, i.e., a slow component that represents TGF and a faster component that most likely represents an intrinsic vascular myogenic mechanism.

Animals↗

Dynamics of renal blood flow autoregulation in rats.

Two separate components could be resolved in tests of the dynamic autoregulation of renal blood flow. The slow component corresponds to the frequency at which spontaneous proximal tubular pressure oscillations are found, and are most likely due to the operation of the TGF. The high frequency component most likely represents an intrinsic vascular, myogenic, mechanism. The gain maximum of the admittance in the frequency range corresponding to the autonomous tubular oscillations indicates that the dynamic characteristics responsible for the occurrence of the spontaneous tubular oscillations must be common to a significant fraction of the total nephron population.

Animals↗

Pharmacokinetics, immune response, and biodistribution of iodine-131-labeled chimeric mouse/human IgG1,k 17-1A monoclonal antibody.

Pharmacokinetics, immunogenicity, and biodistribution of a 131I-labeled mouse/human chimeric monoclonal antibody (C-17-1A) was studied in six metastatic colon cancer patients. Pharmacokinetics obtained from serum radioactivity or chimera concentration were identical after 5 mCi of 131I-C-17-1A with mean alpha half-lives of 17.6 +/- 2.3 and 19.7 +/- 2.9 and mean beta half-lives of 100.9 +/- 16.1 and 106.4 +/- 14.1 hr, respectively. HPLC analysis documented the monomeric chimeric 17-1A without evidence of immune complexes or free 131I. None of the patients developed antibody after 131I-chimeric 17-1A exposure. Radiolocalization occurred in known areas of disease greater than 4 cm in all patients. The half-life of total-body radioactivity was 58 +/- 7 hr by whole-body counts and 64 +/- 13 hr by urine measurements. Whole-body and bone marrow dose estimates ranged from 0.75-1.03 and 0.76-1.05 rad/mCi, respectively. These studies confirm the prolonged circulation and reduced immunogenicity of chimeric 17-1A versus murine 17-1A. Marrow radiation exposure using antibodies with prolonged circulation is a critical factor in planning for radioimmunotherapeutic applications.

Adenocarcinoma↗

Assessing fluoroscopic contrast resolution: a practical and quantitative test tool.

Fluoroscopic contrast resolution is commonly determined at a specified kVp by imaging a test object comprised of targets where contrast decreases gradually and sequentially. Threshold contrast or contrast resolution is the contrast of the lowest contrast target that can be perceived. This approach suffers from two problems. First, test object contrast is specified at a x-ray tube voltage that is not always obtainable in practice. Second, the small change in contrast between adjacent targets contributes to observer variability making consistent and reproducible contrast threshold determinations difficult. Described is a contrast resolution test tool that eliminates or reduces these problems. The novel target arrangement allows one to quickly and easily specify the contrast resolution of a fluoroscopic imaging chain to a precision approximately equal to 0.5%. Tables of target contrast versus x-ray tube potential are developed that permit one to employ the test object for contrast resolution determination over the normal range of tube potentials encountered on clinical units.

Fluoroscopy↗